iNPHORM Publications & Disseminations

Alexandria Ratzki-Leewing PhD, Jason E. Black MSc, Anna R. Kahkoska MD, Bridget L. Ryan PhD, Guangyong Zou PhD, Neil Klar PhD, Kristina Timcevska BMSc, Stewart B. Harris MD. Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States). Diabetes Obes Metab. 2023; 1-12. doi:10.1111/dom.15186

Ratzki-Leewing, A, Black, JE, Ryan, BL, Harris, SB. Real-world risk factors of confirmed or probable COVID-19 in Americans with diabetes: A prospective, community-based study (iNPHORM). Endocrinol Diab Metab. May 29, 2022; 00:e342. PMID: 35644866. doi: 10.1002/edm2.342

Alexandria Ratzki-Leewing, Bridget L. Ryan, Guangyong Zou, Susan Webster-Bogaert, Jason E. Black, Kathryn Stirling, Kristina Timcevska, Nadia Khan, John D. Buchenberger, Joseph W. Dickens JW, Stewart B. Harris "Predicting real-world hypoglycemia risk in American adults with type 1 or 2 diabetes mellitus prescribed insulin and/or secretagogues: Protocol for a prospective, 12-wave internet-based panel survey with email support" Submitted to Journal of Medical Internet Research September 20, 2021 accepted January 6, 2022 JMIR Res Protoc. 2022 Jan 6. doi: 10.2196/33726. Online ahead of print https://pubmed.ncbi.nlm.nih.gov/35025756/ Print version February 11, 2022 https://www.researchprotocols.org/2022/2/e33726/

Ratzki-Leewing AA, Ryan BL, Buchenberger JD, Dickens JW, Black JE,Harris SB. DC21-0128 - "The COVID-19 hinterland: surveilling the self-reported impacts of the pandemic on diabetes management in the USA (cross-sectional results of the iNPHORM study). BMJ Open. 2021 Sep 2;11(9):e049782. doi: 10.1136/bmjopen-2021-049782. https://www.nbi.nlm.nih.gov/pubmed/34475174

Ratzki-Leewing A, Black J, Kahkoska A, Ryan B, Harris S. Real-world estimates of severe hypoglycaemia and associated healthcare utilisation in the US: prospective, longitudinal results of the iNPHORM study. Diabetologia. 2022; 65(Suppl 1):1-469. https://link.springer.com/article/10.1007/s00125-022-05755-w

Alexandria Ratzki-Leewing, Stewart B. Harris, Jason E. Black, Guangyong Zou, Susan Webster-Bogaert, Bridget L. Ryan; 371-P: Predicting Real-World Nonsevere Hypoglycemia in Americans with Diabetes (iNPHORM). Diabetes 1 June 2022; 71 (Supplement_1): 371–P. https://doi.org/10.2337/db22-371-P

Alexandria Ratzki-Leewing, Stewart B. Harris, Jason E. Black, Guangyong Zou, Susan Webster-Bogaert, Bridget L. Ryan; 372-P: Predicting Real-World Severe Hypoglycemia in Americans with Diabetes (iNPHORM). Diabetes 1 June 2022; 71 (Supplement_1): 372–P. https://doi.org/10.2337/db22-372-P

Ratzki-Leewing A, Harris S, Zou GY, Ryan B; A tool not a treatment: the effect of long-term continuous /flash glucose monitoring on real-world hypoglycemia rates (iNPHORM study); Diabetes Technology & Therapeutics. Apr 2022. A-1-A-237. http://doi.org/10.1089/dia.2022.2525.

A.Ratzki-Leewing, S. Harris, S. Webster-Bogaert, G. Zou, B.L. Ryan; Real-world severe hypoglycemia incidence across Canada and the United States; Accepted for Oral Poster International Diabetes Federation Virtual Congress 2021 Diabetes Research and Clinical Practice publication reference in progress

Ratzki-Leewing A, Harris S, Black JE, Khan N, Timcevska K, Ryan BL, Zou GY; COVID-19 Impact on diabetes management (iNPHORM, USA); Can J Diabetes, Volume 45, ISSUE 7, SUPPLEMENT, S3, November 01, 2021 DOI: https://doi.org/10.1016/j.jcjd.2021.09.012

Ratzki-Leewing A, Harris S, Black JE, Ryan BL, Zou GY; How COVID-19 has impacted diabetes management in the United States (iNPHORM study); Diabetologia. 2021 64(Suppl.1): S362 https://doi.org/10.1007/s00125-021-05519-y This abstract was selected by EASD for media press release

Alexandria Ratzki-Leewing, Jason E. Black, Bridget L. Ryan, Guangyong Zou, Stewart B. Harris, London, ON, Canada. Why Some Americans Use Healthcare Following Severe Hypoglycemia, And Why Some Do Not: Baseline Results Of The iNPHORM Study. Diabetes 2021 Jun;70(Supplement 1) 347-P https://doi.org/10.2337/db21-347-P

Ratzki-Leewing A, Harris S, Black J, Stirling K, Zou G, Ryan B. Second-generation basal insulin analogues: first-choice in reducing real-world severe hypoglycemia (baseline results of the iNPHORM study, USA) Diabetes Technology & Therapeutics Vol 23, Supplement 2, 2021 pg A-89 to A-90. http://doi.org/10.1089/dia.2021.2525.abstracts

Ratzki-Leewing A, Harris S, Ryan, B Zou G. Real-world estimates of severe hypoglycemia and associated healthcare utilization in the US: baseline results of the iNPHORM study. Diabetes Technology & Therapeutics Vol 23, Supplement 2, 2021 pg A-140 http://doi.org/10.1089/dia.2021.2525.

Ratzki-Leewing A, Harris SB, Zou G, Ryan BL. Real-world estimates of severe hypoglycaemia and associated healthcare utilisation in the US: baseline results of the iNPHORM study Diabetologia. 2020.63(Suppl.1):750P, S363 https://doi.org/10.1007/s00125-020-05221-5

Ratzki-Leewing A, Ryan BL, Zou GY, Au NH, Webster-Bogaert S, Harris S. Investigating novel predictions of hypoglycemia occurrence using real-world models (iNPHORM Study): a study protocol. Morressier. (2019). https://doi.org/10.26226/MORRESSIER.5DC53540EA541D6CA8493F87